title: A randomized trial of intracervical prostaglandin gel and intravenous oxytocin in prelabor rupture of membranes with unripe cervix at term.
abstract: In order to compare the efficacy of immediate intravenous oxytocin administration and intracervical prostaglandin E2 gel application in premature rupture of membranes with unfavorable cervices at term, 45 term pregnant patients with premature rupture of membranes were randomized into two groups. Twenty women received immediate intravenous oxytocin after cleansing enema while the rest were treated with intracervical prostaglandin E2 gel. Means of maternal age, gestational age, Bishop score at admission and the rates of nulliparity did not show any significant differences between the two groups (p > 0.05). The mean rupture to delivery time was 12.6 +/- 4.4 hours in the oxytocin group and 16.5 +/- 4.5 hours in the prostaglandin group (p < 0.01). Mean birth weights and Apgar scores were insignificant. Cesarean section rates were 24% in the oxytocin group and 5% in the other (p < 0.05). No infectious morbidity was seen in any case. In conclusion, although delivery is delayed with the intracervical prostaglandin approach, cesarean section rate is lowered without an increase in infectious morbidity.
authors.affiliation: Uludağ University Faculty of Medicine, Department of Obstetrics and Gynecology, Bursa, Turkey.
authors.forename: T
authors.initials: T
authors.lastname: Bilgin
authors.forename: M
authors.initials: M
authors.lastname: Kadioğlu
authors.forename: V
authors.initials: V
authors.lastname: Yildirim
authors.forename: C
authors.initials: C
authors.lastname: Cengiz
mesh_terms: D000287:Administration, Topical; D000328:Adult; D015232:Dinoprostone / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000628:therapy*; D005782:Gels; D006801:Humans; D007275:Injections, Intravenous; D010120:Oxytocics / Q000008:administration & dosage / Q000627:therapeutic use*; D010121:Oxytocin / Q000008:administration & dosage / Q000627:therapeutic use*; D011247:Pregnancy; D016896:Treatment Outcome
chemical_list: D005782:Gels; D010120:Oxytocics; D010121:Oxytocin; D015232:Dinoprostone